Tag Archives: Michael Higgins
Ovid Therapeutics Inc (OVID) Gets a Buy Rating from Ladenburg
In a report released today, Michael Higgins from Ladenburg maintained a Buy rating on Ovid Therapeutics Inc (OVID – Research Report), with a price target of $27. The company’s shares opened today at $1.73, close to its 52-week low of
Analysts Are Bullish on Top Healthcare Stocks: Intec Pharma Ltd (NTEC), Iovance Biotherapeutics Inc (IOVA)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intec Pharma Ltd (NTEC – Research Report) and Iovance Biotherapeutics Inc (IOVA – Research Report) with bullish sentiments. Intec Pharma Ltd (NTEC)
Arch Therapeutics Inc (ARTH) Gets a Buy Rating from Ladenburg
In a report released today, Michael Higgins from Ladenburg reiterated a Buy rating on Arch Therapeutics Inc (ARTH – Research Report), with a price target of $1.25. The company’s shares closed yesterday at $0.28, close to its 52-week low of
Novus Therapeutics, Inc. (NVUS) Receives a Buy from Ladenburg
In a report released today, Michael Higgins from Ladenburg reiterated a Buy rating on Novus Therapeutics, Inc. (NVUS – Research Report), with a price target of $10. The company’s shares closed yesterday at $2.22, close to its 52-week low of
Cerecor Inc (CERC) Gets a Buy Rating from Ladenburg
In a report released today, Michael Higgins from Ladenburg reiterated a Buy rating on Cerecor Inc (CERC – Research Report), with a price target of $8. The company’s shares closed on Friday at $5.02. Higgins commented: “We expect CERC-800s’ development
Ladenburg Believes Palatin Technologies (NYSE MKT: PTN) Won’t Stop Here
In a report issued on May 10, Michael Higgins from Ladenburg maintained a Buy rating on Palatin Technologies (PTN – Research Report), with a price target of $2.75. The company’s shares closed on Friday at $1.42, close to its 52-week
